Key Points

  • India’s Sensex fell to a 32-month closing low and the Nifty 50 reached an 18-month low on Thursday, setting the stage for a possible technical rebound.
  • Brent crude traded near $104 a barrel after rising about 4%, increasing concerns about inflation, import costs and pressure on the Indian rupee.
  • Foreign investors sold a net ₹129.44 billion ($1.3 billion) in Indian equities on Thursday, while domestic institutions bought ₹107.03 billion, providing partial support.
hero

Indian shares were poised to recover at the open on Friday after a sharp selloff pushed benchmark indexes to multi-year lows, but elevated oil prices and continued foreign selling threatened to limit gains. The market’s direction reflects a difficult combination of rising global borrowing costs, currency weakness and geopolitical uncertainty, with investors weighing the potential for a short-term technical rebound against broader economic pressures.

Oversold Markets Raise Prospects of a Technical Recovery

The Sensex dropped 1.44% to 71,593.24 on Thursday, its lowest closing level in 32 months. The Nifty 50 fell 1.64% to 22,231.80, marking an 18-month closing low. The declines followed mounting pressure from higher crude prices, rising global bond yields and a weaker rupee, which have collectively reduced risk appetite.

Early indicators pointed to a potentially stronger opening on Friday. GIFT Nifty futures traded at 22,379.5 at 7:41 a.m. India time, suggesting that the Nifty 50 could recover some of the previous session’s losses. Such a move would represent a possible technical rebound after the sharp decline, rather than clear evidence that the broader downward trend has ended. Investors are likely to remain cautious until there is greater clarity on oil prices, foreign capital flows and corporate earnings.

Oil Prices and the Rupee Remain Key Risks

Brent crude hovered near $104 a barrel after gaining approximately 4%, driven by Middle East tensions and concerns about supply disruptions linked to a hurricane in the United States. For India, a major crude importer, higher oil prices can increase the import bill, widen external financing pressures and complicate the inflation outlook.

The pressure on the rupee adds another layer of risk. A weaker currency makes dollar-denominated imports more expensive, potentially reinforcing inflationary pressures and limiting the Reserve Bank of India’s room to support growth through monetary easing. Rising U.S. Treasury yields can also make dollar assets more attractive relative to emerging-market equities, adding to the challenge of retaining foreign investment.

Foreign Selling and Sector-Specific Pressures Weigh on Sentiment

Foreign investors sold a net ₹129.44 billion ($1.3 billion) in Indian equities on Thursday, the largest daily outflow since May 2026. Domestic institutional investors purchased ₹107.03 billion in shares, cushioning some of the selling pressure but failing to prevent the market’s decline.

Technology stocks face additional uncertainty following U.S. regulatory action suspending major Indian IT firms from a green-card-linked Permanent Labor Certification Program. The move adds pressure to a sector already contending with concerns about weak growth, while Tata Consultancy Services’ softer September-quarter results have raised questions about demand and earnings momentum.

The near-term outlook will depend on whether oil prices ease, the rupee stabilizes and foreign selling moderates. Investors will also monitor corporate earnings for signs that companies can sustain profitability despite higher costs and tighter financial conditions. A rebound is possible after the recent selloff, but a durable recovery will likely require improvement in the external environment as well as stronger confidence in India’s earnings outlook.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.
    • omer bar
    • •
    • 6 Min Read
    • •
    • ago 48 minutes

    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments. SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    • ago 48 minutes
    • •
    • 6 Min Read

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 1 hour

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a

    • ago 1 hour
    • •
    • 6 Min Read

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a

    SKN | Could Oracle’s Rising Debt and AI Infrastructure Spending Put Its Growth Strategy Under Pressure?
    • Ronny Mor
    • •
    • 7 Min Read
    • •
    • ago 6 hours

    SKN | Could Oracle’s Rising Debt and AI Infrastructure Spending Put Its Growth Strategy Under Pressure? SKN | Could Oracle’s Rising Debt and AI Infrastructure Spending Put Its Growth Strategy Under Pressure?

    Oracle shares came under significant pressure Thursday as investors assessed the growing financial requirements behind the company’s artificial intelligence infrastructure

    • ago 6 hours
    • •
    • 7 Min Read

    Oracle shares came under significant pressure Thursday as investors assessed the growing financial requirements behind the company’s artificial intelligence infrastructure

    SKN | Moderna and Eli Lilly Lead Healthcare Stocks Higher as Markets Retreat
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 1 day

    SKN | Moderna and Eli Lilly Lead Healthcare Stocks Higher as Markets Retreat SKN | Moderna and Eli Lilly Lead Healthcare Stocks Higher as Markets Retreat

    Healthcare stocks delivered a strong performance on Wednesday, October 7, showing resilience as broader U.S. markets pulled back. Moderna gained

    • ago 1 day
    • •
    • 6 Min Read

    Healthcare stocks delivered a strong performance on Wednesday, October 7, showing resilience as broader U.S. markets pulled back. Moderna gained